 | | PRD_002560 | | Name: | Entolysin A | | Formula: | C81 H141 N17 O23 | | Description: | D-Ser, L-Val, L-Leu, D-Ser, L-Ile amino acids make up a macrocycle within the peptide | | Definition date: | 2025-02-26 | | Last modified: | 2025-02-26 |
|
 | | PRD_002561 | | Name: | Orfamide A | | Formula: | C64 H114 N10 O17 | | Description: | Cyclic lipopeptide | | Definition date: | 2025-02-26 | | Last modified: | 2025-02-26 |
|
 | | PRD_002568 | | Name: | Fluorinated GM1 ganglioside analogue | | Formula: | C49 H84 F2 N2 O27 | | Description: | GM1 ganglioside lipids (monosialotetrahexosylgangliosides) belong to the group of gangliosides within the sphingolipids. Their structure consists of a ceramide backbone linked to an oligosaccharide unit made of five sugar molecules. In this analogue one of the five sugars is fluorinated and the ceramide backbone is replaced by an unsaturated hydrocarbon. | | Definition date: | 2025-02-26 | | Last modified: | 2025-02-26 |
|
 | | PRD_002573 | | Name: | Sialyl-Tn-Ser | | Formula: | C22 H37 N3 O16 | | Description: | Sialyl-Tn (sTn) antigen is a truncated O-glycan containing a sialic acid alpha-2,6 linked to N-acetylgalactosamine (GalNAc) alpha-O-serine or to N-acetylgalactosamine (GalNAc) alpha-O-threonine. | | Definition date: | 2025-02-12 | | Last modified: | 2025-02-12 |
|
 | | PRD_002574 | | Name: | Sialyl-Tn-Thr | | Formula: | C23 H39 N3 O16 | | Description: | Sialyl-Tn (sTn) antigen is a truncated O-glycan containing a sialic acid alpha-2,6 linked to N-acetylgalactosamine (GalNAc) alpha-O-threonine or to N-acetylgalactosamine (GalNAc) alpha-O-serine. | | Definition date: | 2025-02-12 | | Last modified: | 2025-02-12 |
|
 | | PRD_002460 | | Formula: | C20 H39 N3 O5 | | Description: | Calpain I inhibitor | | Definition date: | 2021-02-24 | | Last modified: | 2025-02-04 |
|
 | | PRD_002363 | | Formula: | C73 H120 N20 O13 | | Definition date: | 2020-08-12 | | Last modified: | 2025-02-04 |
|
 | | PRD_002367 | | Name: | ~{N}-[3-[3-(dimethylamino)propylamino]-3-oxidanylidene-propyl]-1-methyl-4-[3-[[1-methyl-4-[[1-methyl-4-[3-[[1-methyl-4-[(1-methylimidazol-2-yl)carbonylamino]pyrrol-2-yl]carbonylamino]propanoylamino]imidazol-2-yl]carbonylamino]pyrrol-2-yl]carbonylamino]propanoylamino]imidazole-2-carboxamide | | Formula: | C41 H55 N17 O8 | | Definition date: | 2022-08-03 | | Last modified: | 2025-02-04 |
|
 | | PRD_002397 | | Formula: | C41 H72 N14 O10 S | | Definition date: | 2021-03-31 | | Last modified: | 2025-02-04 |
|
 | | PRD_002398 | | Formula: | C42 H74 N14 O10 S | | Definition date: | 2021-03-31 | | Last modified: | 2025-02-04 |
|
 | | PRD_002399 | | Formula: | C45 H68 N10 O11 S | | Definition date: | 2021-03-31 | | Last modified: | 2025-02-04 |
|
 | | PRD_002111 | | Name: | ADEP-2B5Me | | Formula: | C41 H56 F2 N6 O8 | | Definition date: | 2014-10-08 | | Last modified: | 2024-12-19 |
|
 | | PRD_002551 | | Name: | Alisporivir | | Formula: | C63 H113 N11 O12 | | Description: | Analogue of cyclosporine A. It is a cyclic undecapeptide. Cyclization is achieved by linking the N- and the C- termini. | | Definition date: | 2024-10-30 | | Last modified: | 2024-10-30 |
|
 | | PRD_002553 | | Name: | Dihydrocyclosporin A | | Formula: | C62 H113 N11 O12 | | Description: | Analogue of cyclosporine A. It is a cyclic undecapeptide. Cyclization is achieved by linking the N- and the C- termini. | | Definition date: | 2024-10-30 | | Last modified: | 2024-10-30 |
|
 | | PRD_002519 | | Name: | MCR-PHE-VAL-PRO-THR-THR-BIF-MAA-BIF-MAA-GLU-ALA-PRO-ALA-NEH inhibitor | | Formula: | C85 H110 N14 O18 S | | Definition date: | 2024-10-16 | | Last modified: | 2024-10-16 |
|
 | | PRD_002520 | | Name: | ACE-PHE-VAL-DAB-THR-THR-PHE-MAA-BIF-YBR inhibitor | | Formula: | C62 H80 N10 O14 | | Definition date: | 2024-10-16 | | Last modified: | 2024-10-16 |
|
 | | PRD_002521 | | Name: | YBX-YC3-VAL-PRO-THR-THR-PHE-MAA-CYS-MN1 inhibitor | | Formula: | C60 H81 N9 O13 S3 | | Definition date: | 2024-10-16 | | Last modified: | 2024-10-16 |
|
 | | PRD_002523 | | Name: | MCR-ALO-MAA-ALA-MAA-NLE-7T2-SER-7T2-ALA-NH2 inhibitor | | Formula: | C49 H70 Cl2 N10 O12 S | | Definition date: | 2024-10-16 | | Last modified: | 2024-10-16 |
|
 | | PRD_002525 | | Name: | PPI-YD5-NLE-7T2-SER-7T2-DPP-GLY-NH2 inhibitor | | Formula: | C43 H59 Cl2 N9 O10 | | Definition date: | 2024-10-16 | | Last modified: | 2024-10-16 |
|
 | | PRD_002554 | | Name: | MCR-ALA-7T2-GLY-004-7T2-SER-7T2-0NC inhibitor | | Formula: | C52 H60 Cl3 N9 O10 S | | Definition date: | 2024-10-16 | | Last modified: | 2024-10-16 |
|
 | | PRD_002558 | | Name: | DGN-DVA-YC3-GLU-PRO-THR-THR-PHE-MAA-A1BC0 inhibitor | | Formula: | C62 H84 N12 O14 S2 | | Definition date: | 2024-10-16 | | Last modified: | 2024-10-16 |
|
 | | PRD_002562 | | Name: | MCR-ALA-7T2-GLY-004-7T2-SER-7T2-ALA-GLY-NH2 inhibitor | | Formula: | C53 H61 Cl3 N10 O11 S | | Definition date: | 2024-10-16 | | Last modified: | 2024-10-16 |
|
 | | PRD_002583 | | Name: | Peptidoglycan disaccharide tetrapeptide | | Formula: | C37 H63 N9 O19 | | Description: | Peptidoglycan is composed of glycan strands and peptide stems. In this instance the glycan strands are made of N-acetylmuramic acid/MurNAc (MUB) and N-acetylglucosamine/GlcNAc (NAG) linked by beta-1,4 glycosidic bonds. Peptide stems, in this instance, are attach to MurNAc and consist of L-alanine, gamma D-glutamine/D-Gln (ZGL), meso-diaminopimelic acid/m-DAP (JGO), and D-alanine (DAP). | | Definition date: | 2024-10-16 | | Last modified: | 2024-10-16 |
|
 | | PRD_002546 | | Name: | NOSO-95179 antibiotic | | Formula: | C43 H79 N18 O11 | | Definition date: | 2024-10-09 | | Last modified: | 2024-10-09 |
|
 | | PRD_002540 | | Name: | evybactin | | Formula: | C64 H91 N21 O21 | | Definition date: | 2024-10-02 | | Last modified: | 2024-10-02 |
|
